Hypoxanthine and xanthine as markers in early diagnosis of foetal diseases.

[1]  A. Mégarbané,et al.  Differences in purine metabolism in patients with Down's syndrome. , 2008, Journal of intellectual disability research : JIDR.

[2]  J. Burn,et al.  Maternal serum screening for Down's syndrome: a survey of midwives' views. , 1997, Public health.

[3]  G. Spoto,et al.  Hypoxanthine and xanthine levels in human aqueous humor from cataractous eyes. , 1996, Life sciences.

[4]  J. Korenberg,et al.  Gene structure and amino acid sequence of the human cone photoreceptor cGMP-phosphodiesterase alpha' subunit (PDEA2) and its chromosomal localization to 10q24. , 1995, Genomics.

[5]  Alan Bird,et al.  Mutations in the human retinal degeneration slow (RDS) gene can cause either retinitis pigmentosa or macular dystrophy , 1993, Nature Genetics.

[6]  V. Sheffield,et al.  Butterfly–shaped pigment dystrophy of the fovea caused by a point mutation in codon 167 of the RDS gene , 1993, Nature Genetics.

[7]  G. Spoto,et al.  A reverse-phase HPLC method for cAMP phosphodiesterase activity. , 1991, Analytical biochemistry.

[8]  J. Canick,et al.  Maternal serum screening for Down's syndrome in early pregnancy. , 1988, BMJ.

[9]  F. Gabreëls,et al.  Reference values for nucleosides and nucleobases in cerebrospinal fluid of children. , 1988, Clinical chemistry.

[10]  R. Puukka,et al.  Levels of some purine metabolizing enzymes in lymphocytes from patients with Down's syndrome. , 1986, Biochemical medicine and metabolic biology.

[11]  C. Gonnet,et al.  Hypoxanthine and xanthine levels determined by high-performance liquid chromatography in plasma, erythrocyte, and urine samples from healthy subjects: the problem of hypoxanthine level evolution as a function of time. , 1983, Analytical biochemistry.

[12]  G. Spoto,et al.  A reverse-phase HPLC method for cyclic nucleotide phosphodiesterases activity and classification. , 1994, Advances in experimental medicine and biology.